Amneal Expands Oncology Offering With Two Denosumab Biosimilars - Life Sciences, Biotechnology & Nanotechnology

On October 12, Amneal announced that it will be adding two denosumab biosimilars to its oncology pipeline, referencing PROLIA and XGEVA.

Related Keywords

United States , ,Mondaq ,Alymsys ,Amneal ,Bdenosumab ,Mabxience ,Orolia ,Vageva ,Food ,Drugs ,Healthcare ,Life Sciences ,Iotechnology Amp Nanotechnology ,